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Developments in managing CF continue to drive dramatic improvements in survival. As newborn screening rolls-out across Europe, CF centres are
increasingly caring for cohorts of patients who have minimal lung disease on diagnosis. With the introduction of mutation-speciﬁc therapies and the
prospect of truly personalised medicine, patients have the potential to enjoy good quality of life in adulthood with ever-increasing life expectancy. The
landmark Standards of Care published in 2005 set out what high quality CF care is and how it can be delivered throughout Europe. This underwent a
fundamental re-write in 2014, resulting in three documents; center framework, quality management and best practice guidelines. This document is a
revision of the latter, updating standards for best practice in key aspects of CF care, in the context of a fast-moving and dynamic ﬁeld.thor.
listair.duff1@nhs.net (A.J.A. Duff).
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154 C. Castellani et al. / Journal of Cystic Fibrosis 17 (2018) 153–178In continuing to give a broad overview of the standards expected for newborn screening, diagnosis, preventative treatment of lung disease,
nutrition, complications, transplant/end of life care and psychological support, this consensus on best practice is expected to prove useful to clinical
teams both in countries where CF care is developing and those with established CF centres. The document is an ECFS product and endorsed by the
CF Network in ERN LUNG and CF Europe.
© 2018 The Author(s). Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society. This is an open access article under the
CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords: Cystic ﬁbrosis; Standards of care; Multidisciplinary management; Best practice; Guidelines; Consensus
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The clinical management of cystic fibrosis (CF) has long been
of paediatric dominance. In the 1940s and 50s, when knowledge of
the disease pathogenesis and availability of treatments were scarce,
few patients entered adulthood [1]. Today this is no longer the case.
In many countries, children account for less than half of the CF
population, with the focus and burden of care gradually shifting
towards adult care. This partly results from the understanding
that the clinical spectrum of CF is wider than originally believed
and the greater diagnostic consideration of phenotypes presenting
in adulthood. However, there is no doubt that the outstanding
attainments in survival predominantly stem from improvements
in care. The establishment of multi-disciplinary centres, creation
of large epidemiological datasets, emphasis on early diagnosis,
together with important new treatments originated by dynamic
pre-clinical and clinical research, have all been instrumental in the
evolution of terrific care. Many adults with CF, some of whom
have now lived beyond their own expectations, enjoy good quality
of life and have jobs or are in further education. Some have families
of their own. Yet despite this positive outlook, there remains
considerable morbidity and early mortality in this group of
patients - a situation particularly manifest in parts of Europe
where available resources and facilities are limited [2–4]. Standards
of care and campaigning for their implementation remain of capital
significance.
The European CF Society (ECFS) has always held that
delivering high quality care is paramount and published standards
of care documents in 2005 [5] and 2014 [6]. The latter version
introduced three distinct work packages; the requisite framework
of the CF center [7], best clinical practice [8] and quality
management in CF care [9]. Standards were established by
achieving consensus amongst a broad spectrum of CF professional
and stakeholders with the project being designed and coordinated
by a dedicated ECFS core working group.
The 2014 publications were intrinsic to a larger project and in
the subsequent years the Standards of Care Working Group
brought forward other initiatives, including a survey on CF
facilities across Eastern Europe [4] and two courses on quality
improvement. It also recognized the importance of continually
updating best practice standards. The time interval since the
previous best practice document reflects fast-moving and dynamic
developments in the field, for example, recommendations for adult
CF care [3] and the expanded use of CFTR modulators [10].
In this revision and update of the 2014 Best Practice Standards
[8] many of the original authors contributed together with new
collaborators. A systematic review of the existing evidence avail-
able from the literature was performed. Whenever consistentresults from well designed, well conducted clinical studies in CF
populations were not available, recommendations developed by
knowledgeable, multidisciplinary panels of experts and patient
representatives were considered, discussed and where appropriate
included in the document. The lead authors of the Newborn
Screening and Early Specialist Care Chapter adopted a Delphi
consensus methodology amongst the ECFS Neonatal Screening
Working Group. Here, initial statements produced by the
authors, were adapted in response to comments from the
Delphi process. After several iterations, complete consensus
was established for all statements.
The manuscript was ratified by the ECFS Board and patient
representatives from CF Europe, and evaluated by three indepen-
dent reviewers.
Whilst much of the structure and content of the 2014 version
remains unchanged, there are important modifications including
new areas and subjects covered, set out across seven chapters and
précised in an executive summary.2. Executive summary of major revisions and additions
2.1. Newborn screening and early specialist care• Incidence declines, resulting from population carrier screening,
should not impair the indication for a newborn screening
programme.
• Factors in making the decision on whether to implement
newborn screening should include available healthcare re-
sources and the ability to provide a clear pathway to treatment.
• Infants with meconium ileus have an increased rate of
false-negative newborn screening test results.
• Families of screened infants with a positive result should be
informed of the function and achievements of CF research
and made aware of opportunities for participation in clinical
trials.2.2. Diagnosis• For mutations not characterized by CFTR2, other evidence to
establish diagnosis may be considered, all requiring accom-
panying sweat chloride confirmation.
• Electrophysiological investigations (nasal potential difference,
intestinal short circuit current measurement) should be
undertaken in a centre with considerable experience of the
procedure.
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• Ivacaftor should be considered as part of the standard of care
in patients with gating mutations.
• Ivacaftor has also shown efficacy in mutations with residual
CFTR function.
• Lumacaftor combined with ivacaftor should be available as
a treatment option for 508del/508del patients.
2.4. Nutrition and metabolic complications
• Fat soluble vitamin levels should be measured at least annually.
• Excessive doses of PERT may result in abdominal pain or
constipation.
• When considering glucose assessment, a single abnormal oral
glucose tolerance test requires confirmation with a second test.
Some centres use continuous glucose monitoring as part of the
diagnostic process.
2.5. Treatment of complications
• CF centers should have established protocols for desensitisation
to allergies to antibiotics.
• Ivacaftor and the combination of lumacaftor/ivacaftor may
cause hepatic impairment. When liver disease is present the
dosing of these drugs may need adjustment.
• Drug-drug interactions, especially after the introduction
of CFTR correctors and modulators, are complications
clinicians should be aware of and when possible prevent by
dose adjustment.
• Gastrointestinal malignancies are more prevalent in patients
with CF than in the healthy population, with a higher yearly
incidence in colorectal cancer and progression of adenoma-
tous colorectal polyps to colorectal cancer. Screening for
colorectal cancer is cost-effective, and should be started at
an age of 40 years.
2.6. Transplantation and end-of-life issues
• Assessment and prioritisation of younger children with CF
requires careful consideration with transplant teams who
have a specific paediatric expertise.
• Ongoing regular contact should be established between
the referring CF centre and the lung transplantation service
about the health status of actively wait-listed patients.
• Potential risks of post-transplant complications in patients
with active Mycobacterium abscessus infection need to be
highlighted.
• The stress that transplantation assessment and being
“wait-listed” can place on the patient and their family
must be pro-actively assessed and managed.
2.7. Psychosocial care
• Recommendations for mental health screening, assessment
and treatment are made in alignment with mental health
guidelines in CF.• The standard on “growing older with CF” has been expanded
to consider living with end-stage disease to balance identi-
fying and treating psychosocial problems with promoting
psychological resilience.
• There are expanded details on supporting the CF Team and
identifying key times of vulnerability.3. Newborn screening and early specialist care
Kevin Southern (UK), Jurg Barben (CH), Anne Munck (FR).
There is clear evidence to support newborn screening (NBS)
for CF. Early recognition provides the foundation for future
management and prevents the delay in diagnosis that has affected
many families in areas that do not screen [11]. Protocols should
be designed to reflect the health service infrastructure and CFTR
genetics of each population and minimise potential negative
impacts. Please refer to the ECFS best practice guidelines on
NBS and on the management of young infants with CF diagnosed
through screening [12,13].
3.1. What population characteristics validate screening newborn
infants for cystic ﬁbrosis?
Health authorities need to balance the benefit/risk ratio of
screening newborns for CF in their population. If the incidence
of CF is b1/7000 births, careful evaluation is required as to
whether NBS is valid. The protocol must be shown to cause the
minimum negative impact possible on the population.
Incidence declines due to population carrier screening should
not impair the indication for an early diagnosis programme as CF
NBS and carrier screening have complementary roles and neither
can replace the other [14]. Other factors inmaking the decision on
whether to implement screening should include available
healthcare resources and the ability to provide a clear pathway
to treatment (see next question).
3.2. What health and social resources are minimally acceptable
for newborn screening to be a valid undertaking?
Infants identified with CF through a NBS programme should
have prompt access to specialist CF care that achieves ECFS
standards. A NBS programme may be a mechanism to better
organise CF services, through the direct referral of infants for
specialist CF care. Countries with limited resources should
consider a pilot study to assess the validity of NBS and the
adequacy of referral services for newly diagnosed infants in
their population.
3.3. What is an acceptable number of repeat tests required for
inadequate dried blood samples for every 1000 infants screened?
The number of requests for repeat dried blood samples should
be monitored and should be b0.5%. More than 20 repeats for
every 1000 infants, is unacceptable (2%).
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(infants referred for clinical assessment and sweat testing)?
Programmes should aim for a minimum positive predictive
value of 0.3 (PPV is the number of infants with a true positive
NBS test divided by the total number of positive NBS tests).
3.5. What is an acceptable number of false negative NBS results?
These are infants with a negative NBS test that are subsequently
diagnosed with CF (a delayed diagnosis)a. Programmes should aim for a minimum sensitivity of 95%.
Sensitivity is the number of true positive NBS results as a
percentage of the total CF population (true positive and false
negatives not including meconium ileus, see below).
b. Infants with meconium ileus (MI) have an increased rate
of false negative NBS test results. This should have little
impact on the timing of diagnosis which should be made
clinically. However paediatric surgeons need to be aware of
this situation. Sensitivity should be calculated and reported
including with and without MI false negative infants.
c. Mechanisms should be in place for the collection of reliable
long-term false negative data.
3.6. What is the maximum acceptable delay between a sweat
test being undertaken and the result given to the family?
The sweat test should be analysed immediately and the
result reported to the family on the same day.
3.7. What is the maximum acceptable age of an infant on the
day they are ﬁrst reviewed by a specialist CF team following
a diagnosis of CF after NBS?
The majority of infants with a confirmed diagnosis after
NBS should be seen by a specialist CF team by 35 days and no
later than 58 days after birth. Programmes that are consistently
missing these targets should undertake a protocol review and
consider alternative strategies.
3.8. What is the minimum acceptable information for families
of an infant recognised to be a carrier of a CF causing CFTR
mutation after NBS?1 Deﬁnition; an infant with a repeatedly intermediate sweat test result, or an
infant with two CFTR gene mutations (one of which has unclear phenotypic
outcome) and a normal or intermediate sweat test result. An intermediate sweat
test result is a sweat chloride value between 30 and 59 mmol/L [16]. The term
CF Screen Positive, Inconclusive Diagnosis (CFSPID) is recommended as the
designation for infants with an unclear diagnosis after NBS [16].a. Families should receive a verbal report of the result. They
should also receive written information to refer to. Information
should also be sent to the family Primary Care Physician.
b. The information should be clear that:
i. The infant does not have CF.
ii. The baby is a healthy carrier.
iii. Future pregnancies for this couple are not free of risk of
CF and the parents may opt for genetic counselling.
iv. There are implications that could affect reproductive
decision making for extended family members and the
infant when they are of child bearing age.3.9. What are the minimum acceptable standards for reporting
a CF diagnosis following NBS to the family?
a. A CF Specialist should discuss the result in person with
the parents.
b. The family should receive written information to read after
the consultation. Information should also be sent to the
family Primary Care Physician.
c. The family should have a clear understanding of short and
long term plans with respect to the child's management.
d. Families of screened infants with a positive result should be
informed of the function and achievements of CF research and
made aware of opportunities for participation in clinical trials.
3.10. What are the minimal acceptable standards for the
recognition and management of infants with an unclear diagnosis1
following NBS?
a. The infant should be reviewed by a CF Specialist.
b. This may be in a CF clinic or a non-CF clinic, if local
circumstances are appropriate.
c. Extended gene sequencing should be undertaken when one
or no mutations are recognised.
d. Sweat testing should be repeated in a centre with considerable
experience (N 150 sweat tests per annum) and sweat chloride
measured by a standard method.
e. Families should receive clear verbal and written information
about the current clinical status of the infant, as well as the plans
for follow-up and assessments. It should be acknowledged that
for many of these infants there may be uncertainty regarding
clinical progress and possible future symptoms. Information
should also be sent to the family Primary Care Physician.
Infants should be managed as per the ECFS guidelines [15].
4. Diagnosis
Isabelle Sermet-Gaudelus (FR), Nataliya Kashirskaya (RU),
Kevin Southern (UK).
It is mandatory to have a high standard of care for diagnostic
evaluation in CF. Diagnostic confirmation is required for children
and adults presenting with suggestive clinical features, but also in
specific situations such as asymptomatic infants with a positive
NBS test or a positive family history.
4.1. What are the requirements to undertake the diagnosis
for CF? [17]
a. To be able to undertake sweat testing according to the
standards described below.
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panel of CFTR mutations for the local population. Access
to extended exon DNA analysis should be available when
required.
c. Resources to undertake clinical assessment including assess-
ment of respiratory condition (respiratory tract culture for
CF-associated pathogens, age appropriate respiratory function
testing and imaging), non-invasive evaluation of exocrine
pancreatic function and sperm count in male adults.
4.2. What are the diagnostic criteria for CF? [17,18]
A positive NBS test result or clinical features suggestive of
CF, including, but not restricted to, diffuse bronchiectasis;
positive sputum cultures for a CF-associated pathogen (especially
P. aeruginosa); exocrine pancreatic insufﬁciency; salt loss
syndrome; and obstructive azoospermia in males and a sweat
chloride N 59 mmol/L and/or two CF causing CFTR mutations
in trans2
The term “mutation” is referred as a “pathogenic variant”,
according to the CFTR-2 database (http://www.CFTR2.org).
For mutations not characterised by CFTR-2, other evidence
may be considered, such as bibliographic data and other genetic
databases (also see paragraph 4.6), all requiring accompanying
sweat chloride confirmation.
4.3. What are the minimal standards for laboratories performing
sweat tests? [19]
a. Sweat collection by experienced personnel (at least 150 sweat
tests per annum) following national or international guidelines
and subject to regular (at least annual) peer review.
b. Use of commercially available equipment approved for
diagnostic use according to the national regulatory require-
ments or EU standards if no local ones are available.
c. Internal quality control (usually three samples) with acceptable
limits of agreement for chloride before each sweat analysis.
d. Regular external quality assurance for the analyses according
to national guidelines.
e. A high number of QNS (Quantity Not Sufficient) rates is a
marker of technical issue. This necessitates renewing training
for personnel experiencing sweat tests.
4.4. What are the diagnostic standards of a sweat test?
a. The quantity of sweat should indicate an adequate rate of
sweat production (15μL for Macroduct™ tube system).
b. The sweat sample should be processed immediately after
sweat collection.
c. A sweat chloride value N59 mmol/L is consistent with a
diagnosis of CF.
d. A sweat chloride value b30 mmol/L makes the diagnosis
of CF unlikely. However, specific CF causing mutations2 On rare occasions two mutations can occur on the same chromosome (called
in cis). For this reason, it is important to check the parental origin of the
mutations to ensure the mutations occur on separate chromosomes (in trans).can be associated with a sweat test below 30 mmol/L. These
include c.3718-2477C N T (3849 + 10kbC N T) and muta-
tions associated with varied clinical consequence such
as c.617T N G (L206W), c.1040G N A (R347H), and
c.3454G N C (D1152H) [21].
e. Individuals with sweat chloride values in the borderline range
(30–59 mmol/L) should undergo a repeat sweat test and
further evaluation in a specialist CF Centre, including detailed
clinical assessment and extensive CFTR gene mutation
analysis [20].4.5. What are the minimal standards for a laboratory performing
mutation analysis for CFTR?a. The laboratory should be able to reliably extract DNA from
dried blood spot samples, whole blood (EDTA) or buccal swabs.
b. Samples should be analysed on a weekly basis to avoid
significant delay.
c. The laboratory should partake in an external quality assurance
exercise with at least annual certification.
d. The primary laboratory should be able to provide a limited
CFTR mutation panel as a starting point that recognises at
least one abnormal allele in N96% of the individuals with CF
in the local population [22].
e. When only one mutation is recognised, extended exon DNA
analysis (gene sequencing) should be available in the primary
laboratory or a secondary laboratory to detect rare mutations
and major deletions or duplications should be sought. The
disease liability of variants detected by DNA sequencing
should be validated against the CFTR-2 database.
f. Novel mutations or variants should be reported to locus
specific databases in order to facilitate future interpretation
of variants of unknown clinical significance.4.6. What is a CF causing mutation?a. A CF-causing mutation is a mutation that causes CF disease
when found in trans with a known CF-causing mutation
[23]. The diagnosis of CF is confirmed in patients with two
CF-causing mutations identified in trans and classified in
the CFTR-2 database (https://www.CFTR2.org) or other
relevant information base. However, the absence of two
CF-causing mutations after extended DNA testing in the
presence of typical clinical or laboratory features of the
disease, or abnormal CFTR bioassays (see paragraph 4.10),
does not rule out CF.
b. Patients with “mutations of varying clinical consequence”
require further evaluation in a Specialist CF Centre. Those
include the mutations that result either in CF or in a
CFTR-related disorder such as diffuse bronchiectasis, con-
genital bilateral absence of vas deferens (CBAVD), recurrent/
chronic idiopathic pancreatitis.
c. Patients carrying mutations of unproven or uncertain clinical
consequence also require further evaluation in a Specialist
CF Centre.
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reporting a diagnosis of CF to a symptomatic patient?a. A positive CF diagnostic test result should be reported
promptly (ideally within 24 hours after sweat result) by the
CF physician.
b. The patient or parent/carer should receive clear written and
verbal information about the disease and be provided with
access to electronic media from the health service/national
patient organization. Contact information on the appropri-
ate CF Centre should be given (in accordance with
treatment pathways for newly diagnosed CF in each
country).
c. Genetic counseling should be offered and contacts for clinical
genetic services provided. This will facilitate primary and
secondary prevention of CF in affected families, including
relatives who may have an increased disease risk.
d. An early follow-up appointment with the CF physician and
the CF centre staff should be arranged to assess understand-
ing (no more than one week). Contact information of the CF
Centre should be given.
e. Patients and parents/carriers should receive advice on other
information resources, in particular the internet.
f. At the initial diagnostic meeting, patients and parents/carriers
should receive information about the model for future
clinical care.
g. Patients and parents should receive information (including
contact details) about the respective national CF patient
organisation.4.8. What are the minimal standards of care and follow-up for
a newly diagnosed patient?
A patient diagnosed with CF should have immediate access to
a Specialist CF Centre that has the multi-disciplinary capacity to
provide care that complies with the ECFS Standards of Care.
4.9. What are the minimal standards of care and follow-up for
patients with symptoms suggestive of CF and intermediate sweat
chloride values? [17]a. A patient, with symptoms suggestive of CF of CF, with a
sweat chloride concentration between 30 and 59 mmol/L, and
either one or no CF causing mutations, should have access
to a Specialist CF Centre for appropriate assessment. It is
important that such patients have long-term care. Follow-up
in a clinic other than a CF clinic may be acceptable in
collaboration with a Specialist CF Centre.
b. Ancillary tests should be performed to detect pancreatic
insufficiency (faecal pancreatic elastase), CBAVD in males,
lung or sinus involvement, or by identifying an ion channel
abnormality (see question 4.10).
c. These patients must be monitored carefully for develop-
ment of any complications and appropriate therapy
implemented.4.10. Should a patient with unclear diagnosis have CFTR
bioassay tests (nasal potential difference, intestinal current
measurement)? [24]
Patients with an unclear diagnosis should be assessed by a
Specialist CF centre. In cases with intermediate sweat test results,
further electrophysiological investigations (nasal potential differ-
ence and intestinal short circuit current measurement), should be
arranged if available. The analyses should be undertaken in a
centre with considerable experience of these procedures.
5. Treatment of lung disease
Felix Ratjen (CA), Patrick Flume (US), Alan Smyth (UK).
Life expectancy in CF has improved dramatically in the last
4 decades [25]. However, the majority of CF patients still die of
respiratory failure [26] and so slowing progression of lung
disease is a primary aim of CF therapy. The basic defect of CF
leads to failure of mucociliary clearance, mucus plugging and
secondary infection, with pathogens such as Staphylococcus
aureus and Pseudomonas aeruginosa. Chronic infection (with
neutrophil-driven inflammation) is punctuated by acute exac-
erbations, following which lung function may fail to return to
baseline levels [27]. Meticulous daily management of lung
disease, together with prompt, aggressive treatment of exacer-
bations are therefore essential to preserve lung function. Best
practice in this area is discussed in this section.
5.1. Should initial or new bacterial infection with Pseudomonas
aeruginosa be treated?
Left untreated, new infection with P. aeruginosa will progress
to chronic infection, which is associatedwith worse lung function,
worse nutrition, more pulmonary exacerbations and a higher
mortality [28]. There is no clear evidence how quickly an
eradication therapy should be commenced, but treatment should
be started promptly (not N4 weeks from receiving a positive
culture result). There is robust evidence that eradication treatment
for P. aeruginosa is effective but no one regimen has yet been
shown to be preferred because of superior efficacy [29]. Options
include 28 days of tobramycin solution for inhalation (TIS)
and up to 3 months of a combination of nebulised colistimethate
and oral ciprofloxacin [30]. Follow-up cultures to document
eradication after treatment are crucial.
5.2. How should chronic bacterial infection with P. aeruginosa
be treated?
When eradication therapy has failed, the diagnosis of chronic
infection is made and long term inhaled antibiotic therapy
should be commenced [31]. USA guidelines recommend TIS
on alternate months for patients over 6 years with chronic
P. aeruginosa, irrespective of the severity of lung disease
and continued indefinitely [32]. Whilst studies are lacking for
children younger than 6 years, treatment at equivalent doses
is also recommended in this age group. The licensed regimen
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treatment. A dry powder inhalation of tobramycin (TOBI
Podhaler™) has been shown to be of equivalent efficacy [33].
Inhaled aztreonam lysine [34] is recommended as an alternative
by both European and US guidelines. Colistimethate (2 MU
twice daily) is used widely in Europe and is now also available as
a dry powder preparation [35]. A specialist physiotherapist
should advise on the timing of inhalational drugs and on
appropriate inhalation techniques.
5.3. Is chronic maintenance therapy indicated to treat other
bacteria?
Whilst individual patients may benefit from prolonged courses
of antibiotics, there is currently little evidence to support chronic
maintenance therapy for bacteria other than P. aeruginosa.
5.4. Is prophylactic therapy indicated to treat bacteria?
Prophylactic flucloxacillin for the first years of life to prevent
infection with Staphylococcus aureus is endorsed by guidelines
in some countries and recommended against in others; its use
remains controversial [30]. There is no evidence to support
prophylactic therapy for other bacteria.
5.5. Is physiotherapy an essential component of chronic
maintenance therapy and is any form of airway clearance superior
to others?
Chest physiotherapy to achieve airway clearance is advo-
cated in UK [36] and US [37] guidelines and should be
available to all CF patients. A recent head-to-head trial [38] has
shown that conventional positive expiratory pressure (PEP) is
superior to high frequency chest wall oscillation (which relies
on expensive equipment). However, in most cases there is little
evidence to support the use of one technique over another. The
airway clearance technique should therefore be tailored to the
individual [39]. Flexibility and appreciation of patient prefer-
ence are essential when prescribing a suitable airway clearance
technique [40]. The CF specialist physiotherapist should have a
comprehensive knowledge of all techniques, CF pathophysiolo-
gy, the rationale for alternative approaches and any contraindi-
cations to specific treatment techniques [39]. Exercise and
physical activity should be integral to the overall physiotherapy
management suggested for every individual with CF, irrespective
of age and disease severity. Reduction in exercise capacity is
associated with a decline in respiratory function and survival
[41].
5.6. What are important components of treating patients during
episodes of clinical deterioration?
5.6.1. Early recognition and treatment
Progression of CF lung disease is characterised by periods of
stability and intermittent episodes of clinical deterioration,
termed pulmonary exacerbations (PEX). There is no agreed
definition of PEX but it is essential that these episodes arediagnosed and treated promptly. Patients experiencing a change
in their symptoms that could represent a PEX need to have
access to a specialised centre without delay. Necessary
diagnostic tools for assessment of PEX include lung function
measurements, microbiological testing and radiological tests.
Treatment of a PEX usually requires antibiotics which can be
administered orally, via inhalation and/or intravenously. If the
patient needs hospital admission for intravenous antibiotic
therapy it is important that this is not delayed.5.6.2. Multidisciplinary care
Treatment of CF exacerbations does not rely on antibiotic
therapy alone and requires a multidisciplinary approach.
Patients should be reviewed regularly by a specialist physio-
therapist who will adjust airway clearance and optimise aerosol
regimens where appropriate. Patients often have a reduced
appetite and require increased caloric intake during a PEX, due
to higher metabolic demands. Access to a specialist dietician is
crucial. Intravenous antibiotics should be selected with input
from a pharmacist and infectious disease/microbiology
specialist.5.6.3. Antibiotic regimen
The pharmacokinetics of antibiotics differ between CF and
non CF individuals and antibiotic dosages need to be adjusted
according to disease specific guidelines (including higher doses
in some cases) [42]. For P. aeruginosa, a combination of two or
more antibiotics is recommended and, although evidence for
choice of antibiotics and optimal treatment duration is lacking,
14 days of intravenous treatment is routine [43]. Some patients
may benefit from longer therapy and this decision should be
based on medical needs rather than resources and costs. Home
intravenous antibiotic therapy is used in individual cases, but a
home care programme needs to assure that all aspects discussed
above are part of the treatment plan. Therefore hospital
treatment remains the standard of care for most patients
requiring intravenous antibiotic therapy.5.6.4. Evaluating response to therapy
It is important to monitor lung function at the beginning and
end of treatment of a PEX to guide decisions regarding
treatment and its duration. Despite intensive treatment about
25% of patients experiencing a PEX requiring intravenous
antibiotic therapy will have a persisting decline in lung function
[27], emphasising the need for maintenance therapies to prevent
exacerbations.5.7. What are the recommended chronic maintenance therapies
to maintain lung health?
A comprehensive review of this topic is beyond the scope of
this document and is available elsewhere [32,44]. Airway
clearance techniques, physical activity and nutritional support
are important components in maintaining lung health; here we
focus on drug therapy only.
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The only mucus degrading agent that has proven efficacy in
CF is dornase alfa. Studies have demonstrated improvements
in lung function and a reduction in PEX in patients regardless
of disease severity [45]. Recent evidence from an analysis
of a large data base suggests that dornase alfa reduces lung
function decline [46]. Treatment effects are lost when treatment
is ceased therefore long-term maintenance therapy is required.
Other mucolytics, such as N acetyl cysteine, have not been
proven to be effective in CF patients [47].
5.7.2. Hydrator therapy
Airways in CF are dehydrated and increasing the airway
surface liquid can be accomplished with osmotic agents that
are called hydrators. The mechanism of action differs from that
of dornase alfa and both approaches are complementary.
Hypertonic saline and mannitol are available as inhaled agents
in Europe. Hypertonic saline (7%) has been shown to reduce
PEX and marginally improve lung function in a systematic
review [48]. Hypertonic saline is currently used in many patients
with moderate to severe lung disease and is supported by
guidelines [32]. Mannitol has been introduced more recently and
improves lung function [49,50]. The drug is available as a dry
powder formulation thereby reducing treatment time. Both agents
act as irritants and require pre-treatment with a bronchodilator
and initial tolerability testing.
5.7.3. Antibiotic therapy
Airway infection in CF can be divided into early, intermit-
tent and chronic infection. This scheme has been useful for
P. aeruginosa infection (see paragraph 5.1) and may also apply
to other bacteria. If eradication fails and chronic infection with P.
aeruginosa develops, inhaled antibiotic therapy has proven
efficacy to reduce pulmonary exacerbations, improve lung
function and respiratory symptoms [31] and is therefore part of
standards of care [30,32]. Inhaled antibiotic therapy should be
administered as long term maintenance therapy with either
single agent therapy or alternating therapy. Alternating
different antibiotics is also used in patients deteriorating
during months off antibiotics, even though the evidence for the
efficacy of this approach is limited. The benefits of treatment
outweigh the risks associated with the development of
antimicrobial resistance which is often overcome by high
topical antibiotic concentrations.
5.7.4. Macrolides
Macrolides are beneficial to CF patients likely due to their
dual effect on infection and inflammation. Whilst not primarily
efficacious against P. aeruginosa, there is evidence suggesting
efficacy if the organism resides in biofilms, which is the case
in chronic P. aeruginosa infection. Maintenance therapy with
azithromycin has been shown to improve lung function and
reduce PEX in chronically infected patients [51] and is part of
recommended care [32]. A reduction in PEX has also been
observed in younger patients not infected with P. aeruginosa
[52]. Some concerns remain, regarding the durability of their
effect and their impact on inducing resistance for other bacteria.5.8. Is airway inﬂammation a target of chronic maintenance
therapy and how should it be treated?
Inflammation is an important component of CF lung disease.
CF airway inflammation is neutrophil dominated and common
anti-inflammatory drugs such as corticosteroids, either systemic
or inhaled, have no proven efficacy in CF patients, outside of
treatment of concomitant asthma. High dose ibuprofen has been
shown to reduce lung function decline in pediatric patients with
preserved lung function [53]. Treatment requires monitoring
of drug levels and despite these promising data it has not
received widespread acceptance. Whilst other anti-inflammatory
therapies are currently being studied, they are neither supported
by sufficient evidence nor available for clinical care at the
present time.
5.9. CFTR modulator therapy - which treatments address the
underlying defect in CF?
Current treatment largely addresses the symptoms caused
by the defective gene while CFTR pharmacotherapy aims to
increase protein expression at the cell surface or its function with
drug therapy [32]. Potentially this treatment strategy could make a
difference in altering or even halting the disease process. Several
drugs targeting specific classes of CFTR defects are currently
being studied; to date two drugs have demonstrated clinical
efficacy. Ivacaftor, a CFTR potentiatior studied initially in patients
with the gating mutation G551D, showed enhanced ion transport
reflected by reductions in sweat chloride concentrations but also
improved clinical measures such as lung function and frequency
of PEX [54]. A subsequent study including patients with other
gating mutations confirmed these positive results [55]. The effect
size of lung function changes exceeded that observed for any drug
therapy available for CF patients to date. While gating mutations
are only found in b5% of patients worldwide, ivacaftor is also a
proof of principle demonstrating the potential impact of CFTR
pharmacotherapy. In patients with gating mutations approved by
regulatory agencies ivacaftor should be considered as part of the
standard of care. Ivacaftor has also shown efficacy in mutations
with residual CFTR function [56]. Lumacaftor, a corrector of
intracellular trafficking of CFTR, when combined with the
potentiator ivacaftor, has been demonstrated to improve lung
function and reduce PEX in patients homozygous for the most
common (508del) mutation [57]. The initial studies included
patients 12 years and older, but positive treatment effects have
also been reported in children 6 to 11 year of age [58]. While
the observed effect size of treatment was smaller than for
ivacaftor in gating mutations, this therapy should be available
as a treatment option for 508del/508del CF patients.
5.10. How should fungal infections and severe/recurrent
Allergic Bronchopulmonary Aspergillosis (ABPA) be treated?
ABPA is a well-characterised complication in CF patients and
should be considered in any patient with clinical deterioration not
responding to antibiotic therapy [30]. Diagnostic tests include
allergy skin testing, measurements of serum IgE and IgE specific
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need to be available to every CF care facility. Treatment is with
oral prednisolone plus/minus antifungal therapy [30].
Aspergillus fumigatus, as well as other fungi, are commonly
found in sputum of CF patients. The majority of these patients
will not develop ABPA and the relevance of fungi beyond APBA
in CF is not entirely clear. More recent evidence suggests that
A. fumigatus may act as a pathogen in at least some CF patients
[59]. Therefore, assessments of cultures in CF patients for fungi
should be available.
5.11. How should we monitor lung disease?
a. A multi-disciplinary team is needed to assess and discuss all
aspects of CF care.
b. Regular monitoring includes assessment of competence of
airway clearance and inhalation technique and monitoring of
adherence (see paragraph 9.4).
c. Clinical assessments should be performed at least every
3 months and at times of symptomatic deterioration [60].
d. As airway infection is a major driver of CF lung disease
airway cultures should be obtained at every clinic visit [30].
e. The microbiological assessment needs to include specific
culture media for the range of CF pathogens to ensure that
relevant organisms are not overlooked.
f. CFTRmodulator therapy requires safetymonitoring that include
liver function testing as the most commonly found laboratory
abnormality, but also assessment for cataracts in children as well
as monitoring of potential drug/drug interactions.
g. Lung function testing guides therapy and should be performed
at every clinic visit in patients old enough to cooperate (usually
5 years and older) [60]. Tests for younger children are currently
under development. Routine lung function testing should
include spirometry performed according to ATS/ERS criteria
[61] and testing pre- and post-bronchodilator should be
available.
h. Chest X-rays are routinely performed on an annual basis in
most CF centres as well as at times of clinical deterioration.
Other imaging modalities, such as high resolution CT scanning,
should be available as well, and are used routinely in some
CF centres.
6. Nutrition and metabolic complications
Anne Munck (FR), Sarah Jane Schwarzenberg (US),
Sue Wolfe (UK).
Nutritional status has a strong positive association with
pulmonary function and survival in CF [62]. Attainment of
normal growth in children and maintenance of adequate
nutrition in adulthood, represent major goals for the CF team.
6.1. What are the goals for nutritional status in patients with CF?
Infants and children should grow normally, with infants
achieving normal weight and height percentiles similar to the
non-CF population by two years of age. Older children andadolescents should grow like healthy peers, with the aim of
being at the 50th percentile for body mass index (BMI). In
adults, absolute BMI should be maintained above 20 kg/m2,
ideally 22 kg/m2 (females) and 23 kg/m2 (males). All patients
should have normal fat soluble vitamin and micronutrient
status. Essential fatty acid status should be monitored, if
the assay is available. Guidelines have been published on
nutritional evaluation and management [5,13,63–71].6.2. How do we monitor nutritional status in routine care?
Until growth ceases, accurate measurement of weight (kg),
length or height (m), and head circumference (cm) (up to
2 years of age) should be made at each hospital visit. In adults,
height should be measured annually. Measurements should be
converted to BMI (N2 years) and compared to national
reference charts. Special attention is needed for toddlers and
adolescents due to rapid growth velocity. Fat soluble vitamins
should be measured at least yearly to permit early detection of
deficiency or excess [13,60,63–70,71–73].6.3. How do we determine exocrine pancreatic insufﬁciency
(EPI) and adequate pancreatic enzyme replacement?
Confirmation of EPI is required. Coefficient of fat absorption
(CFA) is the “gold standard”, but is cumbersome.
Faecal pancreatic elastase-1 (FE1) is a simple and reliable
marker from two weeks of age, in the absence of liquid stools.
Pancreatic sufficient patients should be monitored by annual
FE1 during infancy and childhood and during periods of failure
to thrive, weight loss or diarrhoea.
Pancreatic enzyme replacement therapy (PERT) adequacy is
determined clinically, monitoring nutritional status, signs and
symptoms of malabsorption and excessive appetite with poor
weight gain. Excessive doses of PERT may result in abdominal
pain and constipation. Guidelines for testing for EPI and dosing
of enzymes are available [13,63–65,67–70,74].6.4. What are the main strategies to provide preventive
nutritional care?
CF centres should be familiar with the recommendations for
age-appropriate dietetic advice to be directed by CF dietitians
[5,13,60,63–68,70,74–77]. This includes:a. Assessment of EPI and administration of PERT.
b. Selection of appropriate diet, with attention to a high fat intake.
c. Behavioural therapy to achieve positive mealtime experiences.
d. Providing sodium supplementation, when necessary, with
special awareness in newborn screened infants.
e. Supplementing fat soluble vitamins, as indicated by laboratory
testing.
f. Women with CF who plan their pregnancies should receive
pre-conception advice to improve their nutritional status [75].
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growth?
Evaluation should be triggered by weight loss, decline in
weight or length/height percentile (b2 years of age), decline
in BMI percentile for age and gender (N2 years of age), poor
linear growth (b18 years) or decline in BMI (N18 years). Early
intervention is essential to avoid significant loss of weight or
growth. Diagnosing the cause of malnutrition relies on a careful
assessment and a multidisciplinary approach. Potential causes
include insufficient food intake, excessive stool energy losses
(inadequate PERT or poor adherence), Giardia infection, coeliac
disease, hypercatabolism from pulmonary disease, vomiting
or gastroparesis, glycosuria and psychological impacts of CF
[13,63–65,67–70,74].
6.6. What are the options for interventional nutritional care?
Interventions should be tried stepwise for a limited period
of time or until nutritional status is optimised, depending on
the severity of malnutrition and the age of the patient. Avoid
spending too much time on a single strategy if it is not
producing results.
a. Anticipatory guidance. Reinforcement of adherence to diet,
sodium and enzyme recommendations, using behavioral
intervention for dysfunctional feeding issues in toddlers and
young children [78] or motivational interviewing in older
patients.
b. Moderate malnutrition. Oral supplements should be used
as additional calories in a time-limited trial or temporarily
as meal replacement for ill patients. Temporary nasogastric
(NG)/nasojejunal (NJ) feeds may be useful.
c. Severe malnutrition. Enteral feeding via NG or gastrostomy
tubes usually improves and maintains nutrition in a patient
with CF.
d. Other therapies: Cyproheptadine and growth hormone are
not part of routine management. Parenteral nutrition is only
appropriate when enteral nutrition is impossible or fails.
e. Nutritional rehabilitation can take 3–6 months, so if being
used pre-operatively should start well ahead of an anticipated
operation (e.g. organ transplantation)
[63–65,69,70,76].
6.7. When and how do we screen for diabetes mellitus?
All CF patients who have not been diagnosed with
diabetes/CF-related diabetes (CFRD) including those who
may have had gestational diabetes should be screened during
a period of clinical stability using the standard WHO protocol
annually from age 10 years. A single abnormal oral glucose
tolerance test (OGTT), requires confirmation with a second test.
Some centres now use continuous glucose monitoring as part of
the diagnostic process [79,80]. Refer to the published guidelines
for additional detail. Published guidelines [81–83] suggest more
frequent screening with fasting/post-prandial glucose and/or
OGTT in the following situations: pulmonary exacerbation,initiation of glucocorticoids, enteral tube feeding, planning for
pregnancy, during pregnancy, planned organ transplantation
and where there are symptoms of diabetes.
6.8. What is the current management of CFRD?
Care of patients with CFRD should adhere to standards of care
for all individuals with diabetes; specific variations required for
patients with CF are outlined below [81–83]. Patients with CFRD
require care from a multi-disciplinary management team with
experience in CFRD and in communication and consultation with
the CF team. It is recommended that CFRD be treated with insulin,
not oral diabetic agents. Glucose control may be challenging
during pulmonary exacerbations, requiring more frequent
monitoring and increased insulin. CF nutritional guidelines
apply to CFRD patients. Modification of calorie, fat, protein, or
salt intake as a result of the diagnosis of diabetes is not
appropriate. Monitoring for complications of CFRD is similar
to that for other forms of diabetes. CF patients with impaired
glucose tolerance (IGT) must be monitored closely, particularly
when ill, as they may need insulin therapy intermittently [79].
6.9. Should patients be screened for CF bone disease and if so
how and which factors are involved in the prevention of
reduced bone mineral density?
Low bone mineral density (BMD) is a common complica-
tion in adolescent and adult patients and can occur in children
as clinical status declines. Routine screening for reduced BMD
using dual energy X-ray absorptiometry (DXA) scans from the
age of eight to ten years is recommended, as detailed in
published guidelines [84–86].
Centres should be familiar with the factors contributing to
development of reduced BMD inCF and how to reduce these risks.
The most common risk factors include: pulmonary infections, poor
nutritional status and lack of weight bearing exercise, delayed
puberty, glucocorticoid treatment, hypogonadism, and vitamin D,
calcium and vitamin K deficiencies [84–86].
6.10. What is the current management of reduced bone mineral
density?
Known risk factors should be minimised and dietary intake of
calcium and vitamin D should be optimised to enhance bone
health. The use of bisphosphonates should be considered on an
individual basis, taking bonemineral density, low trauma fracture
history and transplant status into consideration [84–86].
7. Treatment of complications
Harry Heijerman (NL), Barry Plant (ROI), Giovanni Taccetti
(IT).
7.1. Pulmonary complications
Patients with CF may develop a variety of complications
which, although infrequent, occur commonly. The CF centre
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offers standards of diagnosis and management for these
complications as well as resources for additional guidance.
7.1.1. What is the best way to manage pneumothorax in
patients with CF?
Pneumothorax is a complication occurring more commonly in
patients with more severe obstructive airways disease [87]. The
CF centre should have a high suspicion for this complication in
the patient with acute chest pain and shortness of breath and be
able to make the diagnosis using radiologic studies (i.e. chest
X-ray, chest CT). Management guidelines have been published
[88]; the centre should be able to provide basic treatment
(i.e. chest tube, pain control). For those patients who may
need more complicated procedures (e.g. VATS), the centre
should have pre-agreed referral process with Thoracic Surgery
Services where additional novel strategies may also need to be
considered [89].
7.1.2. What is the best way to manage hemoptysis in patients
with CF?
Hemoptysis is a common complication and may range
in severity from scant to massive, defined as N240 mL/d
or N100 mL/d for several days [90]. Management guidelines
have been published [88]. The centre should give the patient
and family clear guidance about when to call, if hemoptysis
occurs, and should be able to provide the recommended
therapies. For severe bleeding, the centre should have access to
interventional radiology (e.g. bronchial artery embolization)
and/or thoracic surgery.
7.1.3. What is the best way to manage respiratory failure in
patients with CF?
The natural history of CF lung disease is progression to
advanced stage airways obstruction and eventual respiratory
failure. The centre should recognise progression to this stage
and have discussions about lung transplant and advanced
healthcare directives (see Chapter 8). The need for supple-
mental oxygen should be assessed in the patient with advanced
stage lung disease (FEV1 b 40% predicted) both at rest and
with exercise [76]. Ventilatory support (e.g. non-invasive
ventilation) should be provided in accordance with the patient's
wishes for palliation of dyspnea [60]. The centre should be able
to assess symptoms and the need for opiates to relieve dyspnea
and pain associated with advanced stage disease [91–93].
7.2. Liver and pancreas complications
7.2.1. What is the best way to manage liver disease in patients
with CF?
Many pancreatic insufficient (PI) CF patients will have
evidence of liver disease ranging in severity from very mild
biliary fibrosis to end-stage cirrhosis. CF related liver
disease (CFLD) is a biliary cirrhosis that usually presents before
age 20 years and can lead to portal hypertension and hepatic
failure [94]. The centre should monitor all patients with routine
physical examination and periodic liver enzyme testing.Guidelines on the use of ultrasonography, ursodeoxycholic acid
(“Urso”), and when to consider a liver biopsy, are available in
published guidelines [94–97].
Patients with portal hypertension should be referred to a
gastroenterologist/hepatologist for screening endoscopy and
management of complications of pulmonary hypertension.
Routine management of CF patients with cirrhosis should
include immunization against hepatitis A and B viruses,
avoidance of NSAIDs and hepatotoxic agents (e.g., alcohol)
and monitoring of the functional status of the liver (i.e.
coagulation, albumin). Recently, CFTR modulators and correc-
tors have been introduced. Ivacaftor and the combination of
lumacaftor/ivacaftor may cause hepatic impairment. When liver
disease is present the dosing of these drugs needs adjustment
[98]. The centre should have a pathway for referral to a liver
transplant program, for those patients with advanced stage liver
disease leading to hepatic failure.
7.2.2. What is the best way to manage cholelithiasis in patients
with CF?
Cholelithiasis is not always symptomatic [99]. The centre
should be suspicious when evaluating the patient with nonspe-
cific abdominal pain and nausea. The centre should have access
to ultrasonography and HIDA scan for assessment of the
gallbladder. For symptomatic gall stones, ursodeoxycholic acid is
ineffective and surgical referral is usually necessary [100].
7.2.3. What is the best way to manage pancreatitis in patients
with CF?
Pancreatitis is a less common complication in the CF
population, but troublesome in some CF individuals with
pancreatic sufficiency [101]. Recurrent acute pancreatitis may
contribute to the transition from pancreatic sufficiency to
insufficiency in CF. The presentation may be a non-specific
abdominal pain, so there should be high suspicion when seeing
a patient with recurrent, unexplained pain and associated
nausea and vomiting. The centre must be able to evaluate with
standard laboratory testing (i.e. amylase, lipase) and imaging
(e.g. ultrasonography, CT, or MRI). Management principles
are no different than those for non-CF pancreatitis. However,
acute pancreatitis is associated with severe dehydration and
in the CF population this may be more severe, demanding
attention to rehydration and electrolyte monitoring. Recently
developed CFTR correctors and potentiators may play a role
in the treatment of recurrent pancreatitis as they stimulate
bicarbonate and fluid secretion in the pancreas [102].
7.3. Gastrointestinal complications
7.3.1. What is the best way to manage gastro-oesophageal
reﬂux disease (GORD) in patients with CF?
GORD occurs commonly in patients with CF, affecting over
36% [26]. The centre should be aware of the signs and
symptoms of GORD and be able to provide, if necessary,
appropriate diagnostic testing (i.e., impedance and pH probe,
upper endoscopy) and treatment [103–107].
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with CF?
Constipation has a slow onset with reduced frequency of
stooling [108]. It is common in CF and may be exacerbated by
use of narcotics. Most of the time constipation responds to
hydration therapy, stool softeners or laxatives (e.g., polyethylene
glycol). Enemas are rarely needed [106,107,109].7.3.3. What is the best way to recognize and manage distal
intestinal obstruction syndrome (DIOS)?
The symptoms of DIOS have acute onset with right lower
quadrant pain [108]. Complete and incomplete DIOS have
been described [109]. The centre should be able to recognize
these complications and have standard protocols for diagno-
sis and treatment based upon published recommendations
[60,107,108,110]. Patients may respond to oral rehydration
combined with stool softeners, but more severe cases may
require IV hydration, nasogastric aspiration, and enemas. For
patients who fail such conservative therapies, referral to a
gastroenterologist with knowledge of DIOS is essential. Pancreatic
enzyme replacement therapy should be re-evaluated in patients
with DIOS [106,107]. Delayed arrival at hospital after the initial
symptoms causes significant morbidity.Medical treatment may fail
only in cases of complete DIOS. Although surgery is the ultimate
resource [111] the centre should have surgeons who know about
this CF complication.7.3.4. What is the best way to prevent ﬁbrosing colonopathy
(FC)?
This is an uncommon complication. At present, the only
clear recommendation to prevent FC is to use the appropriate
dose of pancreatic enzymes, not increase enzyme dose without
clear indication and not exceed 10,000 lipase units/kg/day total
enzyme dose [112–115].7.3.5. What is the best treatment for appendiceal mucocele?
Ultrasonography will aid the diagnosis [116]. In case of
symptoms, appendectomy with resection of the appendix edges
and resection of the caecal tip will avoid risk of recurrence.7.3.6. What is the best way to manage small intestinal bacterial
overgrowth (SIBO) in patients with CF?
SIBO is suspected when patients have diffuse or peri-umbilical
abdominal pain, excessive bowel gas, diarrhea, nausea and mal-
absorption despite adequate enzyme intake. Risk is higher in
patients who have had previous intestinal surgery or are using
narcotics. Although many non-invasive diagnostic procedures
have been used, there is no golden standard test to demonstrate
SIBO [107,117]. It is recommended that diagnosis be made by
a clinical therapeutic trial of metronidazole [118]. Treatment
includes cyclical administration of oral antibiotics effective in the
GI lumen, pre- and probiotics, laxatives and prokinetic drugs
[107]. Due to differences in studies design and outcomemeasures,
scanty evidence exists on the effects of probiotics supplementa-
tion in SIBO [119].7.3.7. What is the best way to manage meconium ileus (MI) in
patients with CF?
MI is a neonatal emergency best handled at a centre familiar
with CF and where a pediatric surgeon with expertise in MI is
available. Early referral to a centre familiar with both
non-surgical and surgical management is essential [120–122].
Complicated MI is more severe, more difficult to treat, and may
require prolonged hospitalization. Post-operative management
may require a centre familiar with management of short bowel.
MI does not predispose to later development of DIOS, however
children with MI have a higher rate of surgery for DIOS [111].7.3.8. Is there an increased risk for GI malignancies in patients
with CF?
In patients with CF, gastrointestinal malignancies are more
prevalent compared to the healthy population. Several studies
show a higher yearly incidence in colorectal cancer and pro-
gression of adenomatous colorectal polyps to colorectal
cancer [123–126]. A recent study shows that screening for
colorectal cancer is cost-effective and should be started at an
age of 40 years [127].7.4. Other complications
7.4.1. What is the best way to manage medication toxicities?
The treatment of CF lung disease can result in complications
due to the treatment and toxicity related to medications,
especially aminoglycosides (e.g. nephro-, oto-, and vestibular
toxicity) [128]. Drug-drug interactions, especially after the
introduction of CFTR correctors and modulators, are compli-
cations clinicians should be aware of and when possible, be
prevented by dose adjustment. The inclusion of a specialized
pharmacist in the CF team is important. The centre should
utilise standard protocols for therapeutic drug monitoring when
using aminoglycosides and follow recommended treatment
dosing [30]. When using intravenous (IV) aminoglycosides,
there should be strict avoidance of NSAIDs to avoid
nephrotoxicity. The centre should perform assessment for
ototoxicity using audiology testing for patients who have
hearing loss or tinnitus, or as part of a routine screening
assessment. The centre should also have access to a clinician
experienced in vestibular assessment.7.4.2. What is the best way to manage nephrolithiasis in
patients with CF?
Nephrolithiasis is common in CF patients [129]. The
centre should be aware of the signs and symptoms associated
with nephrolithiasis and be able to evaluate by urinalysis and
CT-IVP. The metabolic disorder causing kidney stones should be
determined, given the high frequency of enteric hyperoxaluria
[130]. Fluid intake to maintain a high urine output combined with
a low-oxalate and high-calcium diet is appropriate for patients
with kidney stones [130,131]. The centre should have access to a
specialist nephrologist, urologist and interventional radiologist for
complicated nephrolithiasis.
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with CF?
Arthralgias are common symptoms in CF patients [26] but
arthropathy remains poorly understood. The centre should be
aware of this problem. Treatment with analgesics and
anti-inflammatory agents may be needed. Glucocorticoids
and disease-modifying anti-rheumatic drugs may be consid-
ered in refractory cases in consultation with a rheumatologist
who has knowledge of CF [132].
7.4.4. What is the best way to manage sinus disease in patients
with CF?
Chronic sinusitis with or without nasal polyposis is common
in patients with CF and occurs already in early childhood
[26,133]. The centre should routinely evaluate sinus disease and
offer recommended treatment, recognizing that this could be a
source for lower airways infection [134]. It should have access
to diagnostic testing (i.e., CT sinus) and an otolaryngologist
experienced with CF-related sinus disease. Recently developed
CFTR correctors and potentiators may ameliorate sinonasal
disease [135].
7.4.5. What is the best way to manage allergic disease in
patients with CF?
With the exception of ABPA (discussed in paragraph 3.10),
allergic disease is not increased in CF patients and can be
managed similarly to non-CF patients with allergies. Patients
can develop allergies to antibiotics (especially beta-lactams)
that increase the risk of potentially life-threatening reactions
and can complicate medical treatment in patients with ad-
vanced lung disease and frequent exposure to parenteral
antibiotics [136,137]. Hospitalisation at the start of treatment
in patients ‘at risk’, should be considered to improve safety
[138]. The centre should be aware of signs and symptoms
of possible allergic response to treatment and stop that thera-
py accordingly. Following allergologists' advice, the centre
should have established protocols for desensitization should
that therapy be important and with no other treatment options
[137,139–142]. Written instructions on the emergency treat-
ment of allergic reactions should be provided to patients
self-administering intravenous antibiotics at home [139].
7.4.6. What is the best way to avoid complications that result
from chronic indwelling intravenous (IV) catheters in
patients with CF?
An indwelling catheter should be placed in accordance with the
patient's wishes if difficulties exist in performing IV treatment.
The centre should have access to professionals experienced in
the placement of indwelling catheters (e.g. Midline catheters,
peripherally inserted central catheters [PICCs], Port-A-Cath).
Only trained individuals should be able to access the indwelling
catheter, using standardized protocols in infection control and
maintenance of the catheter. Common complications of catheters
include vascular problems (e.g. infection, thrombus, SVC
syndrome) [143–144]. The centre should be keenly aware of
the signs and symptoms of catheter-related complications and be
able to perform proper testing including blood cultures,ultrasonography and contrasted radiology studies to assess
infections and vascular occlusion. Intravascular catheter-related
infections should be managed according to published guidelines
[145,146].
7.4.7. What is the best way to address pregnancy in a CF
patient?
Pregnancy can complicate the management of women with
CF. The centre should always inquire about possible pregnancy
when assessing women who may be fertile, especially when
considering additional medications that are contraindicated in
pregnancy. The pregnant CF patient should always be considered
a high-risk pregnancy because of the potential pulmonary and
nutritional/metabolic complications and should be seen by an
obstetrician experienced in high-risk cases. Management recom-
mendations for pregnant CF patients have been published [75].
7.4.8. What is the best way to address infertility in a CF
patient?
Females with CF can become pregnant and those with good
lung function and nutrition are likely to complete the pregnancy.
In less well females there is the possibility of reduced fertility,
and they should be referred to specialists in fertility services if
there is a perceived inability to become pregnant. Most (98%) CF
males will be azoospermic and should be informed of this finding
at an appropriate age. Sperm analysis should be offered to those
patients interested in knowing their status. Patients should receive
proper counseling regarding fertility options including assisted
reproductive techniques.
8. Transplantation and end-of-life issues
Scott Bell (AU), Alistair Duff (UK), Su Madge (UK),
Thomas Wagner (DE).
Transplantation is an established therapy for end-stage lung
and liver disease in patients with CF. Referral to transplant
services is enhanced by the CF team having an understanding of
the processes leading to a successful transplant. In some patients,
transplant is not a suitable treatment option or does not occur for
various reasons such as death occurring prior to suitable donor
organs becoming available. Effective management of the
end-of-life is vital and requires attention to communication,
symptom control and a multi-disciplinary approach to care,
including expertise in palliative care.
Outcomes for people with CF undergoing lung transplantation
have continued to improve and with 10-year survival rates
approaching 50% [147] and even exceeding this in single-centre
reports [148]. These standards include a series of questions about
the approach to transplantation assessment and end-of-life care,
utilising available published evidence and guidelines. For a
detailed review of all facets of the topic see “Practical guidelines:
Lung transplantation in patients with cystic fibrosis” prepared by
the European Centres of Reference Network for Cystic Fibrosis
(ECORN-CF) Study Group [149] and the ECFS End-of-life Care
Guidelines [150].
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for lung transplantation in patients with CF?
The lead time for assessment and waiting for suitable donor
lungs is variable but can be in excess of two years. Factors
associated with increased mortality, and where referral for
transplantation assessment is recommended [151] are:
a. FEV1% of ≤30 predicted
b. Rapid decline, particularly female and younger patients.
c. Oxygen therapy for hypoxaemia.
d. Hypercapnia.
e. Frequent exacerbation that respond poorly to intravenous
antibiotics.
Earlier referral should be considered in patients with refractory
pneumothorax and recurrent massive haemoptysis [152]. Increased
survival, limited donor availability and differences in organ
allocation schemes have led to prediction models of mortality/
survival which assist with decisions for prioritising patients for
transplantation [153,154]. There remain barriers to referral
for transplant assessment including physicians' perception of
suitability and difficulty in predicting timing of assessment,
and socioeconomic factors [155–157]. The complexities of
timing transplantation-referral require close liaison with the
transplant service. This will also help patients' process complex
information and make informed choices. If in doubt about the
optimal timing for referral for an individual patient it is better to
consider an earlier referral.
Regular and detailed communication with the Transplant
Service is vital to allow regular updates of the clinical
progress of all wait-listed patients. One recent analysis based
on the US CF Foundation Patient Registry of predictors of
non-referral for transplant assessment included low socio-
economic status, older age and B. cepacia complex sputum
culture [155].
Assessment and prioritisation of younger children with CF
requires careful consideration with transplant teams who have a
specific paediatric expertise [158]. Children often have poorer
pre-transplant clinical status and have a higher incidence of
post-transplant infections and diabetes [159].
8.2. What clinical features increase the risk for dying on the
lung transplant waiting list?
Priority for transplantation [152,160,161] should be given to
CF patients with:
a. Oxygen-dependent respiratory failure.
b. Chronic hypercapnia.
c. Pulmonary hypertension [162,163].
d. Under-nutrition - especially female patients.
The limited donor pool determines the number of possible
transplants. National policies optimise the efficiency of
donor-organ allocation differently, depending on donor
identification systems and practical/geographical logistics.Prioritisation of urgent cases is managed at a national level
[164,165]. Aggressive approaches to nutritional restoration
should be considered in all under-nourished patients being
considered for lung transplantation.
8.3. What are the important patient variables, which may
prevent active listing for lung transplantation in CF?
Exclusions for lung transplantation [151] include:
a. Malignancy within 2 years. A disease-free period of 5 years
is generally required. Consideration for cutaneous and some
urogenital cancers may be given.
b. Untreatable dysfunction of another major organ (e.g. heart,
liver, kidney).
c. Chronic extra-pulmonary infection (e.g. hepatitis B, hepatitis C,
HIV).
d. Severe skeletal deformity.
e. Prolonged poor-adherence or irregular clinic attendance.
f. Untreatable psychological condition/s limiting ability to
participate with therapies.
g. Lack of consistent social support system.
h. Substance addiction (e.g. alcohol, tobacco, within previous
6 months).
Most transplant services do not assess patients with chronic
Burkholderia cenocepacia and/or Mycobacteria abscessus (M.
abscessus).
The impact of M. abscessus infection remains unclear,
with recent studies reporting higher rates of post-transplant
infection requiring intensive therapy but not necessarily increased
mortality [166,167], M. abscessus is often associated with
increased morbidity following transplantation. Careful consid-
eration about suitability for listing includes the presence of
smear positive sputum status and presence of multi-resistant
M. abscessus [168].
Other infections (e.g. multi-resistant Pseudomonas aeruginosa,
Scedosporium species and Clostridium difficile) are influenced by
local transplant unit policy and experience and require detailed
discussion.
Combined ‘liver/lung’ or ‘lung only’ transplantation both
require careful consideration in patients with advanced lung
disease and portal hypertension [169]. CF may be associated
with worse outcomes following liver transplantation than for
other indications [170–172].
Re-transplantation may be considered in specific circumstances
in some transplant recipients [173].
8.4. What complications of CF are important to prioritise prior
to lung transplantation?
Optimising nutritional status is a priority for wait-listed
patients, but should not be a strong factor in delaying the listing
process [161].
CFRD is present in 40–50% of patients at assessment and
develops post-transplant in another ~20% of patients. Increased
mortality, infection and rejection-related hospitalisation have
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[174,175]. Optimising control of CFRD is important whilst
wait-listed [175,176].
Chronic kidney disease (CKD) occurs in many adults with
CF and where practical, limiting exposure to nephrotoxic drugs
pre-transplant should be considered [177]. The impact of
long-term systemic use of aminoglycosides before transplanta-
tion on post-transplant renal function is uncertain [178].
Calcineurin inhibitors, hypertension and CFRD have been
associated with CKD following transplantation.
Osteoporosis (24%) and osteopaenia (38%) is reported
in patients with CF [179]. Bisphosphonate therapy may
be required to maintain and improve bone health
pre-transplantation.
Systemic corticosteroids are required in some patients with
advanced lung disease (e.g. ABPA). Limiting daily dose of
prednisolone to b15 mg/day is thought to assist in healing and
reducing post-operative infection risk although – if higher
doses are needed – this should not exclude the patient from
transplantation and reduce post-operative infection risk and
limit further reduction in bone density [180].
Although transplant programmes around the world have
varying guidelines and timelines, individuals presenting
with alcohol or substance abuse/dependency are evaluated to
determine suitability. Recommendations are then made re-
garding rehabilitation and counselling prior to listing, or as a
condition of listing. Improving conditioning by pulmonary
rehabilitation or a structured exercise programme is considered
important for patients who are actively waitlisted. In some
instances patients sign a contract pledging not to use alcohol
or any illicit or addictive substances agreeing to unlimited,
random drug and/or alcohol screening both while awaiting and
following transplantation.
Psychologically it is vital to help patients maintain hope
and counter demoralisation or exhaustion. Patients awaiting
transplantation and their families report that waiting is the most
distressing aspect of the transplant experience. Pre-transplant
care should involve interventions aimed at managing stress
[181].
8.5. Under what circumstances should invasive ventilation be
considered in patients with CF?
The role of invasive ventilation for patients with end-stage
pulmonary disease is controversial and associated with poor
outcomes [182].
Consideration should be made for patients who develop
respiratory failure in the setting of an acute precipitant and
where recovery is anticipated (e.g. massive haemoptysis,
pneumothorax, influenza, post-operative care) [182,183].
Transplantation from the ventilator is associated with higher
early mortality [184] and is only offered in highly selected
cases and not by all transplant services. Usually this only
occurs in patients who have completed transplant work-up prior
to ventilation.
Some transplant services consider transplantation in patients
who have required Extra Corporeal Membrane Oxygenation(ECMO) for severe respiratory failure. Case reports have
suggested excellent outcomes [185–187]. Close communica-
tion between the CF Team and the Transplant Service is
mandatory prior to ECMO initiation. ECMO and veno-venous
lung assist devices have been successfully used to bridge to
lung transplantation [188].
8.6. What therapeutic modalities are important in the palliative
care of the patient with CF?
Early discussions (including the potential for transplantation)
to allow time to psychologically adjust and carefully consider
options is required, particularly as misunderstanding is common.
The physician should initiate a conversation about end-of-life
care with the patient and family and should involve the
multidisciplinary team. Significant psychological intervention
can be required (e.g., management of anticipatory grief and work
with family members) [189].
Symptoms that frequently require control include dyspnoea,
chest pain, headaches, fatigue and poor sleep quality [190]. The
use of narcotic analgesic, anxiolytics, airway clearance support,
psychological strategies, oxygen and non-invasive ventilation
support are important [92,150,191]. Whilst palliative care
should be integrated into routine care of the patient with CF
[192], teams should also have ready access to support from
palliative care colleagues to optimise symptom control, when
required [190,193,194].
The balance between effective, active treatments, whilst
providing adequate symptom control, can be difficult especially
in patients waiting for transplant [190,195]. In a clinical setting
of rapid decline where a person is preparing for transplantation,
there is a need to address end-of-life issues as part of the
medical management. Incorporating both active and palliative
management may be required in such circumstances [181].
Even if transplant is an option, the course of CF can be
changeable and it may be difficult to predict end-of-life. Advance
care planning allows individuals and their CF team to ‘hope for the
best, but plan for the worst’. Advance care planning is a process of
discussion between the patient, CF team and, if requested, family
members and/or friends. Discussions allow concerns, requests or
wishes about future care to be expressed and recorded.
Symptom control does not preclude lung transplantation,
however close communication between CF and Transplant
teams is vital [190].
The death of a patient can have a significant effect on other
patients and staff at the centre. Support of other patients with
CF and staff members should be offered [190].
8.7. What factors are important in deciding on the location of
care for the dying person with CF?
Patients' and families' wishes should be key to making
decisions about where to manage the dying patient and where
practical, measures taken to assist facilitating these wishes [196].
The support available at home to optimally manage all symptoms
is a key consideration (e.g., providing airway clearance support,
the availability of timely symptom control).
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in a familiar environment [197] and in many cases, prefer to
receive care in hospital [190,198].
Active management of patients to maximise symptom
control often continues and potential for conflict between
active management and optimising control symptoms needs to
be carefully considered.
Communication between all team members, community
healthcare team (including primary care), the patient and the
family are vital.
8.8. How should CF-speciﬁc complications be managed
following recovery from lung transplantation?
After lung transplant, management of complications of CF
remains important (e.g. CFRD, osteoporosis, DIOS). In many
cases, the transplant service manages the complete care of
the patient. However, the CF centre should be available to
support where assistance is desired. Psychosocial input is
required to address psychopathology (e.g. drug-related psychosis,
post-traumatic stress reactions).
Even when patients are in good physical health post-transplant
they can face challenges regaining their previously social roles, for
example as family members and partners. Other stressors include
financial problems (including loss of benefits), employment, or
education. Additionally, individuals can feel stressed by the need to
maintain a change in lifestyle (e.g. regular activity, healthy eating,
alcohol and tobacco abstinence) and strict adherence to their
treatment regimen (e.g. timely intake of medication, frequent
follow-up appointments, dietary restrictions, and infection prophy-
laxis). Psychosocial interventions may also be required to support
both the patient and family members throughout this time.
9. Psychosocial support
Alistair Duff (UK), Pavla Hodková (CZ), Maya Kirszenbaum
(FR), Helen Oxley (UK).
Living with CF can be emotionally and physically challenging
for people with CF and their relatives. The condition and its
treatment influence the ability to deal with normal tasks of daily
living and unexpected life events. Good psychosocial care is now
well-integrated into the CF team and there is a substantial body of
literature that establishes the essential elements of the psychosocial
role [60,199,200]. The focus of this chapter is to set out the key
psychosocial issues and make recommendations for appropriate
management. Effective behavioural interventions for feeding
behavior problems in toddlers and young children are addressed
separately in Chapter 6 (6.6). End-of-life issues are addressed in
Chapter 8.
9.1. What are the core elements of supporting parents in the
ﬁrst year, post-diagnosis?
Diagnosis of CF for themajority is by newborn screeningwhich
aims to minimise morbidity and mortality. Yet potential disadvan-
tages must be recognised and addressed [12]. Diagnosis of CF istraumatic, especially in an otherwise healthy infant. Parents can
experience disbelief and dissociation from the diagnosis and baby,
which can last well beyond the first few weeks [199]. Preventative
counseling and emotional support must be offered to assess
parents' (i) understanding of information, (ii) reactions to diagnosis
and, (iii) coping style, support needs and resources.
Parents need to engage in education about their child
growing up with CF, ensuring a balance between managing a
complex health condition and enabling their child to grow with
good self-esteem. Families should be hopeful that their child
will enter adulthood having a good quality of life (QoL) with
achievements similar to non-CF peers. Key tasks are to advise
on:
a. Establishing treatment with baby's daily-routine.
b. Helping parents accept and administer treatment.
c. Communicating to family and friends about the medical
condition.
d. The availability of psychosocial follow-up for parents if
required including couple counselling.
e. Available financial support/benefits/allowances and other
sources of support.
f. Navigating on-line and social media sites to ensure accurate
acquisition of information about CF and new therapies.
9.2. In what ways should mental health problems be prevented,
identiﬁed and addressed?
Rates of depression and anxiety symptoms in people with
CF and parents were established in 2014 [201] with elevated
scores associated with worse adherence, QoL and outcomes.
In response, the International Committee on Mental Health
(ICMH-CF) published guidelines on preventing, assessing and
treating depression and anxiety [202].
The CF team needs to screen annually for mental health
symptoms in people with CF (≥12 years) and parents of children
and young people with CF. The guidelines describe psychometric
screening and follow-up pathways [202]. Where there is no
integrated psychologist, referral to mental health agencies should
be considered. A CF team psychologist should also assess
annually for other significant or emerging emotional health
difficulties and for health management problems (see ECFS
Standards of Care; Centre Framework for access to psychological
professionals [7]).
Psychological intervention, when required, needs to be
supported with consideration of the practical, social, educational
and vocational needs of the patient and their caregivers [203].
9.3. How do we promote psychosocial resilience at key
transition points and address potential associated psychosocial
vulnerability?
Transitions relate to significant changes in developmental
and personal prospects and challenges for people with CF, and
the sense of responsibility these imply.
Key transition points are:
a. Parental adaptation to diagnosis.
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c. Parental- to self-guided treatment.
d. Transition of care from paediatric to adult services.
e. Entering the workplace or further education.
f. Loss of independence (e.g., retirement, loss of activities and
functioning, increased reliance on intrusive treatments and
carers, and facing transplantation).
g. End-of-life care.
Psychosocial resilience is broadly an ability to recover
from negative events with an absence of lasting emotional
disturbance. It is multi-factorial, the elements of which are
not all amenable to change [204]. The primary focus should
be to increase psychosocial support and foster hope
(primarily by paediatric preparation of patients for fulfilling
adult lives and increasing self-efficacy and control). Emo-
tional vulnerability should be addressed pro-actively at each
transition point.
9.4. What are the core components in addressing adherence,
particularly to nebulised therapies?
Improving adherence, particularly to nebulisers, is a key
challenge for the prevention of disease-progression. Successful
psychosocial intervention is determined by (i) the team ethos to
patient care, (ii) forming partnerships with patients to increase
their motivation and, (iii) identifying barriers and actively
supporting patients' efforts to increase treatment.
a. Teams must endorse a collaborative, nurturing and holistic
approach to adherence, based on effective
information-giving and empathic communication. Open
discussion leads to facilitating care that is individually
meaningful and accounts for patient involvement and
making informed choice. Teams should discuss adherence
at every visit, with psychosocial professionals supporting
team-members' efforts to engage patients in conversation
using active-listening skills.
b. Persuading patients with chronic sub-optimal adherence does
not work. Psychosocial professionals must lead on efforts
to address perceptual or emotional barriers to adherence in
patients unwilling to acknowledge problems or who lack
motivation [205].
c. Some techniques are effective but their use depends on the
developmental stage of the patient (e.g., simplifying and
regulating treatments where possible, addressing concerns
about treatment, reinforcement scheduling and
problem-solving). Clinical trials of interventions and
e-application developments are ongoing.
9.5. What are the main components to supporting patients
diagnosed in adolescence/adulthood?
CF diagnosed beyond childhood may arise for a range of
reasons. Patients may often be angry and/or overwhelmed by
information (diagnosis, prognosis, infertility) and technical
aspects of CF. A more flexible and individualised approach toclinical management is needed for the patient, which differs
from the routine care provided to those diagnosed in early
childhood. Emphasis must be placed on prognosis, personal
support, fertility issues, and reviewing what CF knowledge
patients may have acquired and from where (some sources
being misleading) [206,207].9.6. Disordered eating and body image problems in patients
impact on treatment and prognosis. What are the key
components in addressing these?
Competing demands of CF management, including monitor-
ing of nutritional status emphasising weight gain within cultures
that promote ‘thinness’, contribute to confused attitudes towards
eating. Disordered eating and body image problems have been
reported in people with CF [208].
The approach to nutritional management needs to take account
of the patient's attitudes towards eating, shape and personal
appearance, rather than focus simply on calorie intake and weight
gain. Assessment of nutritional intake should include questions
on the above and diet plans incorporating healthy eating ideas.
Educational programmes should be available to inform people
with CF about digestion, calorie consumption and energy usage
in CF. Health professionals working with people with CF should
be equipped to identify disturbed eating behaviours allowing
early detection and joint intervention between dietitian and
psychologist.9.7. How should we tackle the key psychosocial issues of
adulthood and growing older with CF?
Key issues of adulthood and older age are (i) that the normal
tasks of adulthood are compounded by CF, (ii) making
complex decisions (e.g. vocational plans, becoming a parent,
or treatment decisions), (iii) coping with deterioration in health
and loss of mobility and independence, as well as new
complications/diagnoses (e.g., CFRD) and (iv) living with
end-stage disease, considering transplantation and/or engaging
in end-of-life care (see Chapter 6). Challenges of growing
older with CF can lead to, for example, increased anxiety and
depression, low self-esteem and relationship difficulties. CF
teams must be aware of the likelihood of demoralisation
occurring as a consequence of multiple health problems. This
resembles, but is different to depression in personal impact and
treatment [209].
Key approaches are (i) being pro-active during routine clinics
and annual review can help identify emotional, practical and
social support requirements (e.g., employment, fertility,
risk-taking behaviours). Patients tend not to initiate discussion
of these issues [210,211], (ii) early identification of psychological
difficulties affords prevention, (iii) promoting positive coping
strategies is a key part of supporting emotional adjustment in CF
and fostering resilience may be particularly important [212] and,
(iv) referral to a CF team psychosocial professional or external
specialist mental health services.
172 C. Castellani et al. / Journal of Cystic Fibrosis 17 (2018) 153–178Integrated approaches by psychosocial and other CF profes-
sionals, allows highly specialised interventions for complex
problems related to ageing with CF.
9.8. What are the core aspects of training and supporting the
MDT in developing psychosocial skills?
a. All CF team members need good skills in several areas
including compassionate communication, effective infor-
mation giving and recognising and responding to emotional
distress.
b. Some CF team members will require training in more
specific skills such as breaking bad news, recognising
significant psychopathology and referring appropriately,
including to emergency psychiatric services.
c. At the next level of psychological support some trained and
accredited staff may use approaches such as problem-solving,
relaxation training, desensitisation to painful procedures and
psychological “first aid” following difficult life events or
traumatic experiences.
d. Specialist mental health professionals in CF teams (e.g.,
clinical psychologists or psychiatrists) can provide a range
of well-established therapies and strategies through the
diagnosis/formulation of complex emotional health or health
management issues.
The CF team psychological professional also has an
important role in developing the skills and support of other
CF staff in these areas (e.g., via training and supervision).
CF team members can at times experience stress and CF
teams need mechanisms in place to support such emotionally
demanding work. Elements such as team meetings following
particularly distressing events including deaths of patients, and
opportunities for “reflective practice” about complex issues
have been shown to be helpful in other specialties [200]. An
effective system for regular screening for psychological
distress and other CF-related problems also needs to be in
place in all CF services.
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